†Offer is only available to patients with commercial insurance. Offer is NOT available to patients eligible for Medicare, Medicaid, or any other government payer coverage. Out-of-pocket costs may vary. Exclusions and limitations apply. Please see complete Terms and Conditions.
Know more
AS YOU GO
Use the personalized Appointment Preparation Guide to have a conversation with your healthcare provider about what you're experiencing.
Are you a healthcare professional?
The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?
References:
1. AUSTEDO® XR (deutetrabenazine) extended-release tablets/AUSTEDO® tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.
2. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604.
3. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:tre-03-161-4138-1.
4. Warikoo N, Schwartz TL, Citrome L. Tardive dyskinesia. In: Schwartz TL, Megna J, Topel ME, eds. Antipsychotic Drugs. Nova Science Publishers, Inc.; 2013:235-258.
5. Derrow P. What is tardive dyskinesia? Symptoms, causes, diagnosis, treatment, and prevention. Everyday Health. Accessed January 24, 2024. https://www.everydayhealth.com/tardive-dyskinesia/
6. Jackson R, Brams MN, Citrome L, et al. Assessment of the impact of tardive dyskinesia in clinical practice: consensus panel recommendations. Neuropsychiatr Dis Treat. 2021;17:1589-1597.